UBS Group’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $79.5M | Buy |
2,206,765
+854,289
| +63% | +$30.8M | 0.01% | 913 |
|
|
2025
Q1 | $42.1M | Sell |
1,352,476
-353,046
| -21% | -$11M | 0.01% | 1290 |
|
|
2024
Q4 | $43.5M | Buy |
1,705,522
+88,037
| +5% | +$2.25M | 0.01% | 1205 |
|
|
2024
Q3 | $45.8M | Buy |
1,617,485
+332,365
| +26% | +$9.4M | 0.01% | 861 |
|
|
2024
Q2 | $33.9M | Buy |
1,285,120
+585,185
| +84% | +$15.4M | 0.01% | 948 |
|
|
2024
Q1 | $21.3M | Sell |
699,935
-167,060
| -19% | -$5.07M | 0.01% | 1165 |
|
|
2023
Q4 | $24.4M | Buy |
866,995
+122,555
| +16% | +$3.44M | 0.01% | 1007 |
|
|
2023
Q3 | $20.2M | Buy |
744,440
+54,697
| +8% | +$1.48M | 0.01% | 1035 |
|
|
2023
Q2 | $21.2M | Buy |
689,743
+187,788
| +37% | +$5.77M | 0.01% | 1032 |
|
|
2023
Q1 | $18.1M | Sell |
501,955
-233,230
| -32% | -$8.4M | 0.01% | 1072 |
|
|
2022
Q4 | $29.1M | Buy |
735,185
+243,324
| +49% | +$9.62M | 0.01% | 818 |
|
|
2022
Q3 | $19.8M | Buy |
491,861
+294,062
| +149% | +$11.8M | 0.01% | 928 |
|
|
2022
Q2 | $8.32M | Sell |
197,799
-279,890
| -59% | -$11.8M | ﹤0.01% | 1440 |
|
|
2022
Q1 | $18.6M | Buy |
477,689
+26,579
| +6% | +$1.04M | 0.01% | 1097 |
|
|
2021
Q4 | $18M | Buy |
451,110
+159,970
| +55% | +$6.37M | 0.01% | 1180 |
|
|
2021
Q3 | $10.5M | Sell |
291,140
-378,404
| -57% | -$13.7M | ﹤0.01% | 1470 |
|
|
2021
Q2 | $27.4M | Buy |
669,544
+225,011
| +51% | +$9.22M | 0.01% | 931 |
|
|
2021
Q1 | $19.4M | Buy |
444,533
+221,447
| +99% | +$9.66M | 0.01% | 1091 |
|
|
2020
Q4 | $11.2M | Buy |
223,086
+169,536
| +317% | +$8.48M | ﹤0.01% | 1330 |
|
|
2020
Q3 | $2.25M | Buy |
53,550
+44,649
| +502% | +$1.88M | ﹤0.01% | 2321 |
|
|
2020
Q2 | $432K | Buy |
+8,901
| New | +$432K | ﹤0.01% | 3504 |
|